FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Eddie Reed

Research Profile

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Huyen Pham; Eddie Reed; Kathleen E Rodgers; Benjamin M Schwartz; Scott Cruickshank; James E Delmore; Leanne Drummond; Kainoa J Peterson; Gere S diZerega
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.
Baobo Zou; Jinshun Zhao; Christopher F Cuff; Jueli M Li; Q Quentin Li; Eddie Reed
β-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells.
Yi Guo; Michael D Mueller; William Petros; Eddie Reed; Scot C Remick; Pingfu Fu; Honglan Zhu; Jing Jie Yu
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Eddie Reed (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Huyen Pham; Eddie Reed; Kathleen E Rodgers; Benjamin M Schwartz; Scott Cruickshank; James E Delmore; Leanne Drummond; Kainoa J Peterson; Gere S diZerega
Pharmacodynamic stimulation of thrombogenesis by angiotensin (1-7) in recurrent ovarian cancer patients receiving gemcitabine and platinum-based chemotherapy.
Cancer chemotherapy and pharmacology 2013;71(4):965-72.
2013: Baobo Zou; Jinshun Zhao; Christopher F Cuff; Jueli M Li; Q Quentin Li; Eddie Reed
β-Elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells.
Anticancer research 2013;33(3):929-40.
2012: Yi Guo; Michael D Mueller; William Petros; Eddie Reed; Scot C Remick; Pingfu Fu; Honglan Zhu; Jing Jie Yu
Correlations among ERCC1, XPB, UBE2I, EGF, TAL2 and ILF3 revealed by gene signatures of histological subtypes of patients with epithelial ovarian cancer.
Oncology reports 2012;27(1):286-92.
2010: Rui Gao; Douglas K Price; William L Dahut; Eddie Reed; William D Figg
Genetic polymorphisms in XRCC1 associated with radiation therapy in prostate cancer.
Cancer biology & therapy 2010;10(1):13-8.
2010: Gisele Sarosy; Mahrukh M Hussain; Michael Seiden; Arlan F Fuller; Najmosama Nikrui; Annekathryn Goodman; Lori M Minasian; Eddie Reed; Seth M Steinberg; Elise C Kohn
Ten-year follow-up of a phase 2 study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy for poor-prognosis, advanced-stage epithelial ovarian cancer.
Cancer 2010;116(6):1476-84.
2010: David A Clump; Jing Jie Yu; Youngjin Cho; Rui Gao; John Jett; Henry Zot; Jess M Cunnick; Brandi Snyder; Anne C Clump; Melissa Dodrill; Peter Gannett; James E Coad; Robert Shurina; W Douglas Figg; Eddie Reed; Daniel C Flynn
A Polymorphic Variant of AFAP-110 Enhances cSrc Activity.
Translational oncology 2010;3(4):276-85.
2009: Qingdi Q Li; Gangduo Wang; Manchao Zhang; Christopher Cuff; Lan Huang; Eddie Reed
beta-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis.
Oncology reports 2009;22(1):161-70.
2008: Rui Gao; Douglas K Price; Tristan Sissung; Eddie Reed; William D Figg
Ethnic disparities in Americans of European descent versus Americans of African descent related to polymorphic ERCC1, ERCC2, XRCC1, and PARP1.
Molecular cancer therapeutics 2008;7(5):1246-50.
2004: William D Figg; Michael E Franks; David Venzon; Paul H Duray; Michael C Cox; W Marston Linehan; W Van Bingham; James A Eastham; Eddie Reed; Oliver Sartor
Gleason score and pretreatment prostate-specific antigen in survival among patients with stage D2 prostate cancer.
World journal of urology 2004;22(6):425-30.
2003: Mahrukh M Hussain; Herb Kotz; Lori M Minasian; Ahalya Premkumar; Gisele Sarosy; Eddie Reed; Suoping Zhai; Seth M Steinberg; Miranda Raggio; Vyta Kulpa Oliver; William D Figg; Elise C Kohn
Phase II trial of carboxyamidotriazole in patients with relapsed epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(23):4356-63.
2003: MICHELLE RUDEK-RENAUT; Jürgen Venitz; Yuichi Ando; Eddie Reed; James M Pluda; William D Figg
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
Journal of clinical pharmacology 2003;43(10):1124-35.
2003: Michael Hamilton; William Dahut; Otis W Brawley; Patricia Davis; Toni Wells-Jones; David R Kohler; Paul H Duray; David J Liewehr; Nehal J Lakhani; Seth M Steinberg; William D Figg; Eddie Reed
A phase I/II study of high-dose tamoxifen in combination with vinblastine in patients with androgen-independent prostate cancer.
Acta oncologica (Stockholm, Sweden) 2003;42(3):195-201.
2002: Yuichi Ando; Douglas K Price; William L Dahut; Michael C Cox; Eddie Reed; William D Figg
Pharmacogenetic associations of CYP2C19 genotype with in vivo metabolisms and pharmacological effects of thalidomide.
Cancer biology & therapy 2002;1(6):669-73.
2002: Maninderjeet Kaur; Eddie Reed; Oliver Sartor; William Dahut; William D Figg
Suramin's development: what did we learn?
Investigational new drugs 2002;20(2):209-19.
2002: Maria Bonovich; Michelle Olive; Eddie Reed; Brian O'Connell; Charles Vinson
Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines.
Cancer gene therapy 2002;9(1):62-70.
2002: Kelly J Cude; Jeffrey S Montgomery; Douglas K Price; Shannon C Dixon; Randall L Kincaid; Karl F Kovacs; David J Venzon; David J Liewehr; Margaret E Johnson; Eddie Reed; William D Figg
The role of an androgen receptor polymorphism in the clinical outcome of patients with metastatic prostate cancer.
Urologia internationalis 2002;68(1):16-23.
2001: Manasses K Yunmbam; Qingdi Q Li; Edward G Mimnaugh; Ganesh L Kayastha; Jing Jie Yu; L N Jones; Len Neckers; Eddie Reed
Effect of the proteasome inhibitor ALLnL on cisplatin sensitivity in human ovarian tumor cells.
International journal of oncology 2001;19(4):741-8.
2001: William D Figg; William Dahut; Paul H Duray; Michael Hamilton; AC Tompkins; Seth M Steinberg; Elizabeth Jones; Ahalya Premkumar; W Marston Linehan; Mary Kay Floeter; Clara C Chen; S Dixon; David R Kohler; E A Krüger; E Gubish; James M Pluda; Eddie Reed
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):1888-93.
2001: Elise C Kohn; Eddie Reed; Gisele Sarosy; Lori M Minasian; Kenneth S. Bauer; F Bostick-Bruton; Vyta Kulpa; Eiichi Fuse; AC Tompkins; MH Noone; Barry Goldspiel; James M Pluda; William D Figg; Lance A Liotta
A phase I trial of carboxyamido-triazole and paclitaxel for relapsed solid tumors: potential efficacy of the combination and demonstration of pharmacokinetic interaction.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1600-9.
2001: MICHELLE RUDEK-RENAUT; McDonald Horne; William D Figg; William Dahut; V Dyer; James M Pluda; Eddie Reed
Reversible sideroblastic anemia associated with the tetracycline analogue COL-3.
American journal of hematology 2001;67(1):51-3.
2001: J V Ghate; Maria L Turner; MICHELLE RUDEK-RENAUT; William D Figg; William Dahut; V Dyer; James M Pluda; Eddie Reed
Drug-induced lupus associated with COL-3: report of 3 cases.
Archives of dermatology 2001;137(4):471-4.
2001: AH Burstein; Eddie Reed; AC Tompkins; D Venzon; William D Figg
Phenylacetate pharmacokinetics based on iterative two-stage population analysis.
Pharmacotherapy 2001;21(3):281-6.
2001: MICHELLE RUDEK-RENAUT; William D Figg; V Dyer; William Dahut; Maria L Turner; Seth M Steinberg; David J Liewehr; David R Kohler; James M Pluda; Eddie Reed
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(2):584-92.
2001: Qingdi Q Li; Manasses K Yunmbam; X Zhong; Jing Jie Yu; Edward G Mimnaugh; Len Neckers; Eddie Reed
Lactacystin enhances cisplatin sensitivity in resistant human ovarian cancer cell lines via inhibition of DNA repair and ERCC-1 expression.
Cellular and molecular biology (Noisy-le-Grand, France) 2001;47 Online Pub():OL61-72.
2000: M Dabholkar; K Thornton; J Vionnet; F Bostick-Bruton; Jing Jie Yu; Eddie Reed
Increased mRNA levels of xeroderma pigmentosum complementation group B (XPB) and Cockayne's syndrome complementation group B (CSB) without increased mRNA levels of multidrug-resistance gene (MDR1) or metallothionein-II (MT-II) in platinum-resistant human ovarian cancer tissues.
Biochemical pharmacology 2000;60(11):1611-9.
2000: Edward G Mimnaugh; Manasses K Yunmbam; Qingdi Q Li; Paolo Bonvini; Sang-Gu Hwang; Jane Trepel; Eddie Reed; Len Neckers
Prevention of cisplatin-DNA adduct repair and potentiation of cisplatin-induced apoptosis in ovarian carcinoma cells by proteasome inhibitors.
Biochemical pharmacology 2000;60(9):1343-54.
2000: Eddie Reed; M Dabholkar; K Thornton; Carol Thompson; Jing Jie Yu; F Bostick-Bruton
Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues.
Oncology reports 2000;7(5):1123-8.
2000: X Zhong; K Thornton; Eddie Reed
Computer based analyses of the 5'-flanking regions of selected genes involved in the nucleotide excision repair complex.
International journal of oncology 2000;17(2):375-80.
2000: Qingdi Q Li; L Ding; Eddie Reed
Proteasome inhibition suppresses cisplatin-dependent ERCC-1 mRNA expression in human ovarian tumor cells.
Research communications in molecular pathology and pharmacology 2000;107(5-6):387-96.
2000: Jing Jie Yu; A Bicher; Y K Ma; F Bostick-Bruton; Eddie Reed
Absence of evidence for allelic loss or allelic gain for ERCC1 or for XPD in human ovarian cancer cells and tissues.
Cancer letters 2000;151(2):127-32.
2000: Eddie Reed; C S Zerbe; O W Brawley; A Bicher; Seth M Steinberg
Analysis of autopsy evaluations of ovarian cancer patients treated at the National Cancer Institute, 1972-1988.
American journal of clinical oncology 2000;23(2):107-16.
2000: Qingdi Q Li; Jing Jie Yu; C Mu; Manasses K Yunmbam; D Slavsky; C L Cross; F Bostick-Bruton; Eddie Reed
Association between the level of ERCC-1 expression and the repair of cisplatin-induced DNA damage in human ovarian cancer cells.
Anticancer research 2000;20(2A):645-52.
2000: Jing Jie Yu; K B Lee; C Mu; Qingdi Q Li; T V Abernathy; F Bostick-Bruton; Eddie Reed
Comparison of two human ovarian carcinoma cell lines (A2780/CP70 and MCAS) that are equally resistant to platinum, but differ at codon 118 of the ERCC1 gene.
International journal of oncology 2000;16(3):555-60.
1999: Glenn J Bubley; Michael A Carducci; William Dahut; Nancy A Dawson; Danai D Daliani; Mario A Eisenberger; William D Figg; B Freidlin; Susan Halabi; Gary R Hudes; Maha Hussain; Richard S. Kaplan; C Myers; William K Oh; Daniel P Petrylak; Eddie Reed; B Roth; Oliver Sartor; Howard I Scher; J Simons; Victoria Sinibaldi; E J Small; M R Smith; D L Trump; G Wilding
Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(11):3461-7.
1999: Raymond C Bergan; Eddie Reed; Charles E Myers; Donna Headlee; Otis W Brawley; H K Cho; William D Figg; AC Tompkins; W Marston Linehan; David R Kohler; Seth M Steinberg; Mikhail V Blagosklonny
A Phase II study of high-dose tamoxifen in patients with hormone-refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2366-73.
1999: Kenneth S. Bauer; William D Figg; J Michael Hamilton; Elizabeth C Jones; Ahalya Premkumar; Seth M Steinberg; V Dyer; W Marston Linehan; James M Pluda; Eddie Reed
A pharmacokinetically guided Phase II study of carboxyamido-triazole in androgen-independent prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(9):2324-9.
1999: Victor A Sandor; Eddie Reed; Gisele Sarosy; L P Middleton; P Davis; Elise C Kohn
Synchronous inflammatory breast cancer and advanced ovarian carcinoma: a case with prolonged disease-free survival.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(5):585-8.
1999: H K Cho; Richard M Lush; David L Bartlett; H Richard Alexander; Peter C Wu; Steven Libutti; KB Lee; David J Venzon; Kenneth S. Bauer; Eddie Reed; William D Figg
Pharmacokinetics of cisplatin administered by continuous hyperthermic peritoneal perfusion (CHPP) to patients with peritoneal carcinomatosis.
Journal of clinical pharmacology 1999;39(4):394-401.
1999: Qingdi Q Li; Li Zhang; B Tsang; Kevin Gardner; F Bostick-Bruton; Eddie Reed
Phorbol ester exposure activates an AP-1-mediated increase in ERCC-1 messenger RNA expression in human ovarian tumor cells.
Cellular and molecular life sciences : CMLS 1999;55(3):456-66.
1999: J Horti; Shannon C Dixon; C J Logothetis; Y Guo; Eddie Reed; William D Figg
Increased transcriptional activity of prostate-specific antigen in the presence of TNP-470, an angiogenesis inhibitor.
British journal of cancer 1999;79(9-10):1588-93.
1999: Qingdi Q Li; B Tsang; F Bostick-Bruton; Eddie Reed
Modulation of excision repair cross complementation group 1 (ERCC-1) mRNA expression by pharmacological agents in human ovarian carcinoma cells.
Biochemical pharmacology 1999;57(4):347-53.
1999: Eddie Reed
Cisplatin.
Cancer chemotherapy and biological response modifiers 1999;18():144-51.
1999: Adrian M Senderowicz; R Reid; Donna Headlee; T Abornathy; J Horti; Richard M Lush; Eddie Reed; William D Figg; Edward A Sausville
A phase II trial of gallium nitrate in patients with androgen-metastatic prostate cancer.
Urologia internationalis 1999;63(2):120-5.
1999: William D Figg; Sangeeta Raje; Kenneth S. Bauer; AC Tompkins; David Venzon; Raymond C Bergan; A Chen; Michael Hamilton; James M Pluda; Eddie Reed
Pharmacokinetics of thalidomide in an elderly prostate cancer population.
Journal of pharmaceutical sciences 1999;88(1):121-5.
1999: T V Abernathy; K B Lee; R J Parker; Eddie Reed
The measurement of cadmium in biological materials, using graphite furnace atomic absorption spectrometry with Zeeman background correction.
Oncology reports 1999;6(1):155-9.
1998: Kenneth S. Bauer; Elise C Kohn; Richard M Lush; Seth M Steinberg; P Davis; David R Kohler; Eddie Reed; William D Figg
Pharmacokinetics and relative bioavailability of carboxyamido-triazole with respect to food and time of administration: use of a single model for simultaneous determination of changing parameters.
Journal of pharmacokinetics and biopharmaceutics 1998;26(6):673-87.
1998: JD Shapiro; M L Rothenberg; Gisele Sarosy; Seth M Steinberg; D O Adamo; Eddie Reed; R F Ozols; Elise C Kohn
Dose intensive combination platinum and cyclophosphamide in the treatment of patients with advanced untreated epithelial ovarian cancer.
Cancer 1998;83(9):1980-8.
1998: Qingdi Q Li; L Ding; Jing Jie Yu; C Mu; B Tsang; F Bostick-Bruton; Eddie Reed
Cisplatin and phorbol ester independently induce ERCC-1 protein in human ovarian carcinoma cells.
International journal of oncology 1998;13(5):987-92.
1998: Eddie Reed
Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy.
Cancer treatment reviews 1998;24(5):331-44.
1998: David L Bartlett; J F Buell; Steven Libutti; Eddie Reed; KB Lee; William D Figg; David J Venzon; H Richard Alexander
A phase I trial of continuous hyperthermic peritoneal perfusion with tumor necrosis factor and cisplatin in the treatment of peritoneal carcinomatosis.
Cancer 1998;83(6):1251-61.
1998: Qingdi Q Li; Kevin Gardner; Li Zhang; B Tsang; F Bostick-Bruton; Eddie Reed
Cisplatin induction of ERCC-1 mRNA expression in A2780/CP70 human ovarian cancer cells.
The Journal of biological chemistry 1998;273(36):23419-25.
1998: Eddie Reed
Nucleotide excision repair and anti-cancer chemotherapy.
Cytotechnology 1998;27(1-3):187-201.
1998: Qingdi Q Li; F Bostick-Bruton; Eddie Reed
Effect of interleukin-1 alpha and tumour necrosis factor-alpha on cisplatin-induced ERCC-1 mRNA expression in a human ovarian carcinoma cell line.
Anticancer research 1998;18(4A):2283-7.
1998: Jing Jie Yu; C Mu; M Dabholkar; Y Guo; F Bostick-Bruton; Eddie Reed
Alternative splicing of ERCC1 and cisplatin-DNA adduct repair in human tumor cell lines.
International journal of molecular medicine 1998;1(3):617-20.
1998: A Thibault; William D Figg; Raymond C Bergan; Richard M Lush; Charles E Myers; AC Tompkins; Eddie Reed; D Samid
A phase II study of 5-aza-2'deoxycytidine (decitabine) in hormone independent metastatic (D2) prostate cancer.
Tumori 1998;84(1):87-9.
1998: Nancy A Dawson; William D Figg; Otis W Brawley; Raymond C Bergan; MR Cooper; Adrian M Senderowicz; Donna Headlee; Seth M Steinberg; M Sutherland; Nicholas Patronas; Edward A Sausville; W Marston Linehan; Eddie Reed; Oliver Sartor
Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(1):37-44.
1998: Eddie Reed
Should cost be considered in the overall evaluation of phase II clinical trials of new antineoplastic therapies? A response.
Cancer investigation 1998;16(2):135-9; discussion 142-3.
1998: Shannon C Dixon; J Horti; Y Guo; Eddie Reed; William D Figg
Methods for extracting and amplifying genomic DNA isolated from frozen serum.
Nature biotechnology 1998;16(1):91-4.
1997: Jing Jie Yu; C Mu; K B Lee; A Okamoto; E L Reed; F Bostick-Bruton; K C Mitchell; Eddie Reed
A nucleotide polymorphism in ERCC1 in human ovarian cancer cell lines and tumor tissues.
Mutation research 1997;382(1-2):13-20.
1997: Raymond C Bergan; R G Walls; William D Figg; Nancy A Dawson; Donna Headlee; AC Tompkins; Seth M Steinberg; Eddie Reed
Similar clinical outcomes in African-American and non-African-American males treated with suramin for metastatic prostate cancer.
Journal of the National Medical Association 1997;89(9):622-8.
1997: A Bicher; K Ault; A Kimmelman; David M Gershenson; Eddie Reed; B Liang
Loss of heterozygosity in human ovarian cancer on chromosome 19q.
Gynecologic oncology 1997;66(1):36-40.
1997: William D Figg; Glenn S Kroog; Paul H Duray; McClellan Walther; N Patronas; Oliver Sartor; Eddie Reed
Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma.
Cancer 1997;79(10):1964-8.
1997: Elise C Kohn; William D Figg; Gisele Sarosy; Kenneth S. Bauer; P A Davis; M J Soltis; A Thompkins; Lance A Liotta; Eddie Reed
Phase I trial of micronized formulation carboxyamidotriazole in patients with refractory solid tumors: pharmacokinetics, clinical outcome, and comparison of formulations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1985-93.
1997: G Y Ma; David L Bartlett; Eddie Reed; William D Figg; Richard M Lush; KB Lee; Steven Libutti; H Richard Alexander
Continuous hyperthermic peritoneal perfusion with cisplatin for the treatment of peritoneal mesothelioma.
The cancer journal from Scientific American 1997;3(3):174-9.
1997: William D Figg; Michaele C Christian; Richard M Lush; Charles J. Link; P Davis; Elise C Kohn; Gisele Sarosy; M L Rothenberg; R B Weiss; N Ryan; J Jacobs; Eddie Reed
Pharmacokinetics of elemental platinum (ultrafiltrate and total) after a thirty minute intravenous infusion of ormaplatin.
Biopharmaceutics & drug disposition 1997;18(4):347-59.
1997: Nancy A Dawson; William D Figg; MR Cooper; Oliver Sartor; Raymond C Bergan; Adrian M Senderowicz; Seth M Steinberg; AC Tompkins; B Weinberger; Edward A Sausville; Eddie Reed; Charles E Myers
Phase II trial of suramin, leuprolide, and flutamide in previously untreated metastatic prostate cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(4):1470-7.
1997: Shannon C Dixon; A Zalles; C Giordano; Richard M Lush; David Venzon; Eddie Reed; William D Figg
In vitro effect of gallium nitrate when combined with ketoconazole in the prostate cancer cell line PC-3.
Cancer letters 1997;113(1-2):111-6.
1997: Eddie Reed
Cisplatin.
Cancer chemotherapy and biological response modifiers 1997;17():132-8.
1997: William D Figg; James M Pluda; Richard M Lush; MW Saville; Kathleen M Wyvill; Eddie Reed; Robert Yarchoan
The pharmacokinetics of TNP-470, a new angiogenesis inhibitor.
Pharmacotherapy 1997;17(1):91-7.
1996: O Rixe; W Ortuzar; M Alvarez; R Parker; Eddie Reed; KD Paull; Tito Fojo
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel.
Biochemical pharmacology 1996;52(12):1855-65.
1996: Richard M Lush; William D Figg; James M Pluda; R Bitton; Donna Headlee; David R Kohler; Eddie Reed; Oliver Sartor; MR Cooper
A phase I study of pentosan polysulfate sodium in patients with advanced malignancies.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):939-44.
1996: M D Dabholkar; M S Berger; J A Vionnet; L Overton; Carol Thompson; F Bostick-Bruton; Jing Jie Yu; J R Silber; Eddie Reed
Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain.
Molecular carcinogenesis 1996;17(1):1-7.
1996: Elise C Kohn; Gisele Sarosy; P Davis; M Christian; C E Link; Frederick P Ognibene; W F Sindelar; J Jacob; Seth M Steinberg; A Premkumar; Eddie Reed
A phase I/II study of dose-intense paclitaxel with cisplatin and cyclophosphamide as initial therapy of poor-prognosis advanced-stage epithelial ovarian cancer.
Gynecologic oncology 1996;62(2):181-91.
1996: Eddie Reed; Gisele Sarosy; Elise C Kohn; M Christian; Charles J. Link; Barry Goldspiel; P Davis; J Jacob; M Maher
A phase I study of paclitaxel and cyclophosphamide in recurrent adenocarcinoma of the ovary.
Gynecologic oncology 1996;61(3):349-53.
1996: A Thibault; D Samid; AC Tompkins; William D Figg; MR Cooper; R J Hohl; Jane Trepel; B Liang; N Patronas; D J Venzon; Eddie Reed; Charles E Myers
Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(3):483-91.
1996: M N Middleman; Richard M Lush; Oliver Sartor; Eddie Reed; William D Figg
Treatment approaches for metastatic cancer of the prostate based on recent molecular evidence.
Cancer treatment reviews 1996;22(2):105-18.
1996: Elise C Kohn; Eddie Reed; Gisele Sarosy; M Christian; Charles J. Link; K Cole; William D Figg; P A Davis; J Jacob; Barry Goldspiel; Lance A Liotta
Clinical investigation of a cytostatic calcium influx inhibitor in patients with refractory cancers.
Cancer research 1996;56(3):569-73.
1996: C J Bowden; William D Figg; Nancy A Dawson; Oliver Sartor; R J Bitton; M S Weinberger; Donna Headlee; Eddie Reed; Charles E Myers; MR Cooper
A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
Cancer chemotherapy and pharmacology 1996;39(1-2):1-8.
1996: William D Figg; K Ammerman; N Patronas; Seth M Steinberg; R G Walls; Nancy A Dawson; Eddie Reed; Oliver Sartor
Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer.
Cancer investigation 1996;14(6):513-7.
1996: William D Figg; Nancy A Dawson; M N Middleman; Otis W Brawley; Richard M Lush; Adrian M Senderowicz; S H Steinberg; AC Tompkins; Eddie Reed; Oliver Sartor
Flutamide withdrawal and concomitant initiation of aminoglutethimide in patients with hormone refractory prostate cancer.
Acta oncologica (Stockholm, Sweden) 1996;35(6):763-5.
1996: Eddie Reed; R Bitton; Gisele Sarosy; Elise C Kohn
Paclitaxel dose intensity.
The Journal of infusional chemotherapy 1996;6(2):59-63.
1996: M Dabholkar; Eddie Reed
Cisplatin.
Cancer chemotherapy and biological response modifiers 1996;16():88-110.
1995: B C Liang; D A Ross; Eddie Reed
Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas.
Journal of neuro-oncology 1995;26(1):17-23.
1995: R J Bitton; William D Figg; D J Venzon; Marinos C Dalakas; C Bowden; Donna Headlee; Eddie Reed; Charles E Myers; MR Cooper
Pharmacologic variables associated with the development of neurologic toxicity in patients treated with suramin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2223-9.
1995: William D Figg; Kristina A Cole; Eddie Reed; Seth M Steinberg; S C Piscitelli; P A Davis; M J Soltis; J Jacob; S Boudoulas; Barry Goldspiel
Pharmacokinetics of orally administered carboxyamido-triazole, an inhibitor of calcium-mediated signal transduction.
Clinical cancer research : an official journal of the American Association for Cancer Research 1995;1(8):797-803.
1995: M N Benchekroun; R Parker; M Dabholkar; Eddie Reed; B K Sinha
Effects of interleukin-1 alpha on DNA repair in human ovarian carcinoma (NIH:OVCAR-3) cells: implications in the mechanism of sensitization of cis-diamminedichloroplatinum(II).
Molecular pharmacology 1995;47(6):1255-60.
1995: Eddie Reed; Elise C Kohn; Gisele Sarosy; M Dabholkar; P Davis; J Jacob; M Maher
Paclitaxel, cisplatin, and cyclophosphamide in human ovarian cancer: molecular rationale and early clinical results.
Seminars in oncology 1995;22(3 Suppl 6):90-6.
1995: William D Figg; A Thibault; MR Cooper; R Reid; Donna Headlee; Nancy A Dawson; David R Kohler; Eddie Reed; Oliver Sartor
A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer.
Cancer 1995;75(8):2159-64.
1995: William D Figg; Oliver Sartor; MR Cooper; A Thibault; Raymond C Bergan; Nancy A Dawson; Eddie Reed; Charles E Myers
Prostate specific antigen decline following the discontinuation of flutamide in patients with stage D2 prostate cancer.
The American journal of medicine 1995;98(4):412-4.
1995: M D Dabholkar; M S Berger; J A Vionnet; Charles E Egwuagu; J R Silber; Jing Jie Yu; Eddie Reed
Malignant and nonmalignant brain tissues differ in their messenger RNA expression patterns for ERCC1 and ERCC2.
Cancer research 1995;55(6):1261-6.
1995: R J Bitton; William D Figg; Eddie Reed
A preliminary risk-benefit assessment of paclitaxel.
Drug safety : an international journal of medical toxicology and drug experience 1995;12(3):196-208.
1995: K B Lee; R J Parker; Eddie Reed
Effect of cadmium on human ovarian cancer cells with acquired cisplatin resistance.
Cancer letters 1995;88(1):57-66.
1995: Charles J. Link; Gisele Sarosy; Elise C Kohn; Michaele C Christian; P Davis; D O Adamo; Eddie Reed
Cutaneous manifestations of Taxol therapy.
Investigational new drugs 1995;13(3):261-3.
1994: William D Figg; MR Cooper; A Thibault; Donna Headlee; J Humphrey; Raymond C Bergan; Eddie Reed; Oliver Sartor
Acute renal toxicity associated with suramin in the treatment of prostate cancer.
Cancer 1994;74(5):1612-4.
1994: M Dabholkar; J Vionnet; F Bostick-Bruton; Jing Jie Yu; Eddie Reed
Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy.
The Journal of clinical investigation 1994;94(2):703-8.
1994: Eddie Reed
The use of colony-stimulating factors as bone marrow support for systemic anticancer chemotherapy.
Journal of the National Medical Association 1994;86(6):459-64.
1994: Charles J. Link; A Bicher; Elise C Kohn; Michaele C Christian; P A Davis; D O Adamo; Eddie Reed; Gisele Sarosy
Flexible granulocyte colony-stimulating factor dosing in ovarian cancer patients who receive dose-intense taxol therapy.
Blood 1994;83(5):1188-92.
1994: M Dabholkar; M Christian; Eddie Reed
Cisplatin.
Cancer chemotherapy and biological response modifiers 1994;15():87-98.
1994: Eddie Reed
Promising new developments in the systemic treatment of ovarian cancer.
Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians 1994;5(1):16-21.
1993: Eddie Reed; John Janik; M A Bookman; M Rothenberg; J Smith; R C Young; R F Ozols; L VanderMolen; Elise C Kohn; J L Jacob
High-dose carboplatin and recombinant granulocyte-macrophage colony-stimulating factor in advanced-stage recurrent ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2118-26.
1993: S M Jerian; Gisele Sarosy; Charles J. Link; H J Fingert; Eddie Reed; Elise C Kohn
Incapacitating autonomic neuropathy precipitated by taxol.
Gynecologic oncology 1993;51(2):277-80.
1993: K B Lee; R J Parker; Vilhelm A Bohr; T Cornelison; Eddie Reed
Cisplatin sensitivity/resistance in UV repair-deficient Chinese hamster ovary cells of complementation groups 1 and 3.
Carcinogenesis 1993;14(10):2177-80.
1993: M N Benchekroun; R Parker; Eddie Reed; B K Sinha
Inhibition of DNA repair and sensitization of cisplatin in human ovarian carcinoma cells by interleukin-1 alpha.
Biochemical and biophysical research communications 1993;195(1):294-300.
1993: Eddie Reed; R J Parker; I Gill; A Bicher; M Dabholkar; J A Vionnet; F Bostick-Bruton; Robert E Tarone; F M Muggia
Platinum-DNA adduct in leukocyte DNA of a cohort of 49 patients with 24 different types of malignancies.
Cancer research 1993;53(16):3694-9.
1993: T L Cornelison; Eddie Reed
Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin.
Gynecologic oncology 1993;50(2):147-58.
1993: Gisele Sarosy; Eddie Reed
Taxol dose intensification and its clinical implications.
Journal of the National Medical Association 1993;85(6):427-31.
1993: S Gupta-Burt; H Shamkhani; Eddie Reed; Robert E Tarone; Carmen J Allegra; L H Pai; Miriam C Poirier
Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 1993;2(3):229-34.
1993: A Bicher; Elise C Kohn; Gisele Sarosy; P Davis; D O Adamo; J Jacob; M Christian; Eddie Reed
The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor.
Anti-cancer drugs 1993;4(2):141-8.
1993: Miriam C Poirier; Eddie Reed; H Shamkhani; Robert E Tarone; S Gupta-Burt
Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
Environmental health perspectives 1993;99():149-54.
1993: T L Cornelison; Eddie Reed
Dose intensity analysis of high-dose carboplatin in refractory ovarian carcinoma relative to age.
Cancer 1993;71(2 Suppl):650-5.
1993: R J Parker; J A Vionnet; F Bostick-Bruton; Eddie Reed
Ormaplatin sensitivity/resistance in human ovarian cancer cells made resistant to cisplatin.
Cancer research 1993;53(2):242-7.
1993: A Bicher; Gisele Sarosy; Elise C Kohn; D O Adamo; P Davis; J Jacob; B A Chabner; Eddie Reed
Age does not influence taxol dose intensity in recurrent carcinoma of the ovary.
Cancer 1993;71(2 Suppl):594-600.
1993: M Dabholkar; Eddie Reed
Cisplatin.
Cancer chemotherapy and biological response modifiers 1993;14():86-97.
1993: R J Parker; M D Dabholkar; K B Lee; F Bostick-Bruton; Eddie Reed
Taxol effect on cisplatin sensitivity and cisplatin cellular accumulation in human ovarian cancer cells.
Journal of the National Cancer Institute. Monographs 1993;(15):83-8.
1993: Arbuck Susan; H Strauss; eric rowinsky; M Christian; M Suffness; J Adams; M Oakes; W McGuire; Eddie Reed; H Gibbs
A reassessment of cardiac toxicity associated with Taxol.
Journal of the National Cancer Institute. Monographs 1993;(15):117-30.
1993: M Dabholkar; F Bostick-Bruton; C Weber; Charles E Egwuagu; Vilhelm A Bohr; Eddie Reed
Expression of excision repair genes in non-malignant bone marrow from cancer patients.
Mutation research 1993;293(2):151-60.
1992: M Dabholkar; L Bradshaw; R J Parker; I Gill; F Bostick-Bruton; F M Muggia; Eddie Reed
Cisplatin-DNA damage and repair in peripheral blood leukocytes in vivo and in vitro.
Environmental health perspectives 1992;98():53-9.
1992: M Dabholkar; F Bostick-Bruton; C Weber; Vilhelm A Bohr; Charles E Egwuagu; Eddie Reed
ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients.
Journal of the National Cancer Institute 1992;84(19):1512-7.
1992: L H Pai; S M Swain; D J Venzon; Eddie Reed; Miriam C Poirier; S Gupta-Burt; A M Denicoff; Carmen J Allegra
Therapy of patients with metastatic breast cancer with 5-fluorouracil, leucovorin and carboplatin.
Anti-cancer drugs 1992;3(5):463-9.
1992: W Zhen; Charles J. Link; P M O'Connor; Eddie Reed; R Parker; S B Howell; Vilhelm A Bohr
Increased gene-specific repair of cisplatin interstrand cross-links in cisplatin-resistant human ovarian cancer cell lines.
Molecular and cellular biology 1992;12(9):3689-98.
1992: Gisele Sarosy; Elise C Kohn; D A Stone; M Rothenberg; J Jacob; D O Adamo; Frederick P Ognibene; Robert Cunnion; Eddie Reed
Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(7):1165-70.
1992: M Dabholkar; R Parker; Eddie Reed
Determinants of cisplatin sensitivity in non-malignant non-drug-selected human T cell lines.
Mutation research 1992;274(1):45-56.
1992: M L Rothenberg; R F Ozols; E Glatstein; Seth M Steinberg; Eddie Reed; R C Young
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(5):727-34.
1992: M Dabholkar; Eddie Reed
Host cell reactivation of cisplatin-damaged plasmid DNA in human non-T leukocyte cell lines.
Cancer letters 1992;63(2):143-50.
1992: Miriam C Poirier; Eddie Reed; C L Litterst; D Katz; S Gupta-Burt
Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Cancer research 1992;52(1):149-53.
1992: Miriam C Poirier; H Shamkhani; Eddie Reed; Robert E Tarone; S Gupta-Burt
DNA adducts induced by platinum drug chemotherapeutic agents in human tissues.
Progress in clinical and biological research 1992;374():197-212.
1992: Eddie Reed; MR Cooper; R V LaRocca; F Bostick-Bruton; Charles E Myers
Suramin in advanced platinum-resistant ovarian cancer.
European journal of cancer (Oxford, England : 1990) 1992;28A(4-5):864-6.
1991: Eddie Reed
Alkylating agents and platinum: is clinical resistance simply a tumor cell phenomenon?
Current opinion in oncology 1991;3(6):1055-9.
1991: R J Parker; I Gill; Robert E Tarone; J A Vionnet; S Grunberg; F M Muggia; Eddie Reed
Platinum-DNA damage in leukocyte DNA of patients receiving carboplatin and cisplatin chemotherapy, measured by atomic absorption spectrometry.
Carcinogenesis 1991;12(7):1253-8.
1991: Eddie Reed; J Jacob; Otis W Brawley
Measures of renal function in patients with cisplatin-related chronic renal disease.
Journal of the National Medical Association 1991;83(6):522-6.
1991: J C Jones; W P Zhen; Eddie Reed; R J Parker; Aziz Sancar; Vilhelm A Bohr
Gene-specific formation and repair of cisplatin intrastrand adducts and interstrand cross-links in Chinese hamster ovary cells.
The Journal of biological chemistry 1991;266(11):7101-7.
1991: R J Parker; A Eastman; F Bostick-Bruton; Eddie Reed
Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.
The Journal of clinical investigation 1991;87(3):772-7.
1991: I Gill; F M Muggia; P M Terheggen; C Michael; R J Parker; V Kortes; S Grunberg; M C Christian; Eddie Reed; L den Engelse
Dose-escalation study of carboplatin (day 1) and cisplatin (day 3): tolerance and relation to leukocyte and buccal cell platinum--DNA adducts.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1991;2(2):115-21.
1990: Eddie Reed; S Gupta-Burt; C L Litterst; Miriam C Poirier
Characterization of the DNA damage recognized by an antiserum elicited against cis-diamminedichloroplatinum (II)-modified DNA.
Carcinogenesis 1990;11(12):2117-21.
1990: M Dabholkar; A Eastman; Eddie Reed
Host-cell reactivation of cisplatin-damaged pRSVcat in a human lymphoid cell line.
Carcinogenesis 1990;11(10):1761-4.
1990: Henry Hennings; R A Shores; Miriam C Poirier; Eddie Reed; Robert E Tarone; Stuart H Yuspa
Enhanced malignant conversion of benign mouse skin tumors by cisplatin.
Journal of the National Cancer Institute 1990;82(10):836-40.
1990: Eddie Reed; Y Ostchega; Seth M Steinberg; Stuart H Yuspa; R C Young; R F Ozols; Miriam C Poirier
Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Cancer research 1990;50(8):2256-60.
1990: Miriam C Poirier; Ainsley Weston; S Gupta-Burt; Eddie Reed
Measurement of DNA adducts by immunoassays.
Basic life sciences 1990;53():1-11.
1990: R J Parker; Miriam C Poirier; F Bostick-Bruton; J Vionnet; Vilhelm A Bohr; Eddie Reed
Peripheral blood leukocytes as a surrogate marker for cisplatin drug resistance: studies of adduct levels and the repair gene ERCC1.
Basic life sciences 1990;53():251-61.
1989: Miriam C Poirier; S H Liou; Eddie Reed; Paul T Strickland; M S Tockman
Determination of carcinogen-DNA adducts by immunoassay.
Journal of UOEH 1989;11 Suppl():353-67.
1988: Eddie Reed; R F Ozols; Robert E Tarone; Stuart H Yuspa; Miriam C Poirier
The measurement of cisplatin-DNA adduct levels in testicular cancer patients.
Carcinogenesis 1988;9(10):1909-11.
1988: Miriam C Poirier; Merrill J Egorin; A M Fichtinger-Schepman; Stuart H Yuspa; Eddie Reed
DNA adducts of cisplatin and carboplatin in tissues of cancer patients.
IARC scientific publications 1988;(89):313-20.